Ligand Pharmaceuticals acquires XOMA in $739M all-cash deal
Ligand Pharmaceuticals has agreed to acquire competitor XOMA, a biotech royalty company, for $739 million in a cash-only deal. This acquisition will enhance Ligand's portfolio by incorporating over 120 additional assets. The transaction is anticipated to finalize in the third quarter of 2026.
Key facts
- Ligand Pharmaceuticals is acquiring XOMA for $739 million
- The acquisition is an all-cash deal
- More than 120 assets will be added to Ligand's portfolio
- The deal is expected to close in Q3 2026
Entities
Institutions
- Ligand Pharmaceuticals
- XOMA
Sources
- Quartz —